Literature DB >> 12627474

Enhanced production of amyloid precursor protein mRNA by peripheral mononuclear blood cell in Alzheimer's disease.

Sanduo Jiang1, Mingyuan Zhang, Daming Ren, Guomei Tang, Sicui Lin, Yiping Qian, Ye Zhang, Kaida Jiang, Fei Li, Dongxiang Wang.   

Abstract

Previous studies have suggested the involvement of amyloid precursor protein (APP) in Alzheimer's disease (AD), as exons 16 and 17 of the APP gene mutations have been found in some familial AD patients. Furthermore, overexpression and deposition of the beta amyloid peptide, a proteolytic product of APP, have been considered as a pathological hallmark of Alzheimer's disease. Therefore, it is of particular interest to determine the expression of APP gene at the transcription level for better understanding of the roles of APP gene in AD pathogenesis. In this work, we employed the quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) to quantify APP mRNA transcripts in the peripheral mononuclear blood cells (PMBC) of 52 Alzheimer's patients, 28 vascular dementia (VD) patients, and 60 healthy elderly controls. The results showed that the amount (mean +/- SEM) of APP transcripts per microgram of total cDNA was 4.05 +/- 0.27, 2.73 +/- 0.33, and 2.59 +/- 0.27 amole in AD, VD, and healthy controls, respectively. There was a significant increase (P < 0.05) in the expression of APP mRNA transcripts in AD compared with that in VD or in healthy controls. Thus, our data indicated that variation of APP gene expression in PMBC might be a pathogenic source of Alzheimer's disease. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12627474     DOI: 10.1002/ajmg.b.10067

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  8 in total

Review 1.  Endothelial LRP1 - A Potential Target for the Treatment of Alzheimer's Disease : Theme: Drug Discovery, Development and Delivery in Alzheimer's Disease Guest Editor: Davide Brambilla.

Authors:  Steffen E Storck; Claus U Pietrzik
Journal:  Pharm Res       Date:  2017-09-25       Impact factor: 4.200

2.  Plasma levels of soluble amyloid precursor protein β in symptomatic Alzheimer's disease.

Authors:  Panagiotis Alexopoulos; Lena-Sophie Gleixner; Lukas Werle; Felix Buhl; Nathalie Thierjung; Evangelia Giourou; Simone M Kagerbauer; Philippos Gourzis; Hubert Kübler; Timo Grimmer; Igor Yakushev; Jan Martin; Alexander Kurz; Robert Perneczky
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-06-10       Impact factor: 5.270

3.  Immunophenotypes in the circulation of patients with mild cognitive impairment.

Authors:  Shino Magaki; Steven M Yellon; Claudius Mueller; Wolff M Kirsch
Journal:  J Psychiatr Res       Date:  2007-02-23       Impact factor: 4.791

4.  Increased production of inflammatory cytokines in mild cognitive impairment.

Authors:  Shino Magaki; Claudius Mueller; Cindy Dickson; Wolff Kirsch
Journal:  Exp Gerontol       Date:  2006-11-07       Impact factor: 4.032

5.  The Blood-Brain Barrier in Alzheimer's Disease.

Authors:  Steffen E Storck; Anika M S Hartz; Claus U Pietrzik
Journal:  Handb Exp Pharmacol       Date:  2022

6.  Soluble amyloid precursor protein β as blood-based biomarker of Alzheimer's disease.

Authors:  R Perneczky; L H Guo; S M Kagerbauer; L Werle; A Kurz; J Martin; P Alexopoulos
Journal:  Transl Psychiatry       Date:  2013-02-19       Impact factor: 6.222

7.  Moderate blast exposure alters gene expression and levels of amyloid precursor protein.

Authors:  Jessica Gill; Ann Cashion; Nicole Osier; Lindsay Arcurio; Vida Motamedi; Kristine C Dell; Walter Carr; Hyung-Suk Kim; Sijung Yun; Peter Walker; Stephen Ahlers; Matthew LoPresti; Angela Yarnell
Journal:  Neurol Genet       Date:  2017-09-27

8.  Amyloid precursor protein glycosylation is altered in the brain of patients with Alzheimer's disease.

Authors:  Claudia P Boix; Inmaculada Lopez-Font; Inmaculada Cuchillo-Ibañez; Javier Sáez-Valero
Journal:  Alzheimers Res Ther       Date:  2020-08-12       Impact factor: 6.982

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.